# Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects

> **NCT04818398** · PHASE1 · COMPLETED · sponsor: **Daiichi Sankyo Co., Ltd.** · enrollment: 48 (actual)

## Conditions studied

- Fibrodysplasia Ossificans Progressiva

## Interventions

- **DRUG:** DS-6016a
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04818398
- **Lead sponsor:** Daiichi Sankyo Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-01
- **Primary completion:** 2021-12-24
- **Final completion:** 2022-07-26
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04818398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04818398, "Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04818398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*